NANOG and neoplasm: Although LY2228820 only slightly inhibited tumor growth rate (Figure 5E), it markedly inhibited paclitaxel-induced increases of ALDH+ (Figure 5F) and mammosphere-forming (Figure 5G) cells and of expression of Nanog, Sox2, and Klf4 (Figure 5H).